Trial Profile
A randomized, double-blind, multicenter study comparing MDX-010 [ipilimumab] monotherapy, MDX-010 in combination with a melanoma peptide vaccine [MDX 1379], and melanoma vaccine monotherapy in HLA-A2 0201-positive patients with previously treated unresectable stage III or IV melanoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; MDX 1379
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Bristol-Myers Squibb; Medarex
- 12 Oct 2017 Results of pooled data from three trial (CheckMate-067, CheckMate-037 and MDX010-20) assessing utility values across treatments and lines of treatment using data in advanced melanoma for two immuno-oncology agents, nivolumab and ipilimumab, were presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 13 May 2016 Results of comparison of overall survival data for ipilimumab, vemurafenib and dacarbazine from three trials including this published in the BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
- 01 Dec 2015 Results related to immunoregulatory predictors of efficacy from NCT00094653 and NCT00495066 published in the Cancer Research.